Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Publication date: 18/10/2017 Abstract Authors’ conclusions: exposure to infliximab is not associated with an increased risk of malignancy or hemophagocytic syndrome in children with inflammatory boweldisease. Exposure to thiopurines is an important antecedent for the development of these complications. Reviewers’ commentary: the use of infliximab and other biological therapies does not seem to increase the risk of onset of tumors in the medium term, although it would be advisable to prolong the follow-up (...) Infliximab treatment in inflammatory boweldisease does not increase the risk of malignancy Infliximab treatment in inflammatory boweldisease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password
Management of rectal gastrointestinal stromal tumorGastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor (...) receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep
Lonsurf for Metastatic ColorectalCancer – Details Lonsurf for Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Lonsurf for Metastatic ColorectalCancer – Details Lonsurf for Metastatic ColorectalCancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic ColorectalCancer Funding Request For the treatment of adult patients with metastatic (...) colorectalcancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date November 6, 2017 Submission Deemed Complete November 13, 2017 Submission Type New Drug
as the presence of alternate sized repetitive DNA sequences which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectalcancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. As well, detecting MSI is used diagnostically for tumor detection and classification. For these reasons, microsatellite instability analysis (...) Microsatellite instability in colorectalcancerColorectalcancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectalcancer may be categorized into three main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island
Gastrointestinal stromal tumor of the esophagus: current issues of diagnosis, surgery and drug therapy Gastrointestinal stromal tumors (GISTs) often arise in the stomach and small intestine, while esophageal GISTs are rare. Due to their rarity, clinicopathological data on esophageal GISTs are extremely limited, and this results in a lack of clear recommendations concerning optimal surgical management for esophageal GISTs. It is difficult to distinguish esophageal GIST from leiomyoma, the most (...) frequent esophageal mesenchymal tumor, prior to resection, because the two types of tumors appear similar on computed tomography (CT), endoscopic ultrasound (EUS), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Fine-needle aspiration biopsy (FNAB) under EUS enables definitive diagnosis, but it is often avoided because scarring could make enucleation more difficult and increase the risk of tumor dissemination by capsule destruction. Esophageal segmental and wedge resections
Vectibix for Left Sided Metastatic ColorectalCancer — Details Vectibix for Left Sided Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Vectibix for Left Sided Metastatic ColorectalCancer – Details Vectibix for Left Sided Metastatic ColorectalCancer – Details Project Number pCODR 10118 Brand Name Vectibix Generic Name Panitumumab Strength 20 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic ColorectalCancer Funding Request In combination (...) with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 31, 2015 Manufacturer Amgen Canada Inc. Submitter Amgen Canada Inc. Submission Date September 8, 2017 Submission Deemed Complete September 15, 2017 Submission Type New Indication Prioritization Requested Not Requested Stakeholder Input Deadline ‡ September 22, 2017 Check-point meeting October 30, 2017 pERC
Erbitux for Left Sided Metastatic ColorectalCancer – Details Erbitux for Left Sided Metastatic ColorectalCancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic ColorectalCancer – Details Erbitux for Left Sided Metastatic ColorectalCancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic ColorectalCancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date
ColonicNeoplasmsColorectalNeoplasms Humans 2016 1 27 6 0 2016 1 27 6 0 2018 1 19 6 0 ppublish 26811349 mdw039 10.1093/annonc/mdw039 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectalcarcinoma' by Rosati et al. 26811349 2018 01 18 2018 12 02 1569-8041 27 5 2016 05 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectalcarcinoma' by Rosati et al. 957-8
di Ricerche Farmacologiche Mario Negri, Milan firstname.lastname@example.org. eng Letter Comment 2016 02 23 England Ann Oncol 9007735 0923-7534 0 Carcinoembryonic Antigen IM Ann Oncol. 2016 Feb;27(2):274-80 26578734 Ann Oncol. 2016 May;27(5):957-8 26811349 Carcinoembryonic Antigen ColonicNeoplasmsColorectalNeoplasms Humans 2016 2 26 6 0 2016 2 26 6 0 2018 1 19 6 0 ppublish 26912556 mdw076 10.1093/annonc/mdw076 (...) Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectalcarcinoma' by Hines et al. 26912556 2018 01 18 2018 12 02 1569-8041 27 6 2016 06 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectalcarcinoma' by Hines et al. 1171
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectalcancer: learning from a clinical case Constitutive activation of HER2-dependent intracellular signalling by HER2 gene amplification or by HER2 mutations has been demonstrated as a mechanism of primary and secondary cancer resistance to cetuximab or panitumumab in preclinical and clinical models of metastatic colorectalcancer (mCRC). Both HER2 Amplification for Colorectal (...) Cancer Enhanced Stratification (HERACLES) cohort A and My Pathway clinical trials provided clinical evidence that anti-HER2 therapies could be active in these patients.HER2 gene amplification and HER2 protein overexpression analysis were performed in tumour tissue by fluorescence in situ hybridisation and immunohistochemistry. HER2 positivity was defined according to HERACLES CRC-specific HER2 scoring criteria. DNA analysis for multiple assessment of gene mutations or amplifications was carried out
Neoadjuvant therapy for gastrointestinal stromal tumor Molecular-targeting therapy using tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors (GISTs). Likewise, imatinib would be effective in the neoadjuvant therapy for high-risk GIST. Neoadjuvant therapy may have the potential to increase the complete resection rate and to avoid the surgical rupture by decreasing the tumor size. Thereby, it is expected that improvement of recurrence (...) rate and survival rate can be obtained by neoadjuvant therapy. Neoadjuvant therapy is also expected to be favored from the viewpoint of organ/function preservation by tumor shrinkage. The existing results of clinical trials established the feasibility of neoadjuvant imatinib therapy. However, proof of the survival effectiveness of neoadjuvant imatinib therapy has not been sufficiently demonstrated. The aim of this article is to introduce previous evidence and strategies regarding neoadjuvant
Molecular characterization and pathogenesis of gastrointestinal stromal tumor Most gastrointestinal stromal tumors (GISTs) harbor activating mutations in the receptor tyrosine kinase gene KIT or platelet-derived growth factor receptor alpha (PDGFRA), and the resultant activation of downstream signals plays a pivotal role in the development of GISTs. The sites of the tyrosine kinase gene mutations are associated with the biological behavior of GISTs, including risk category, clinical outcome (...) and drug response. Mutations in RAS signaling pathway genes, including KRAS and BRAF, have also been reported in KIT/PDGFRA wild-type GISTs, though they are rare. Neurofibromin 1 (NF1) is a tumor suppressor gene mutated in neurofibromatosis type 1. Patients with NF1 mutations are at high risk of developing GISTs. Recent findings suggest that altered expression or mutation of members of succinate dehydrogenase (SDH) heterotetramer are causally associated with GIST development through induction
gastrointestinalGImalignancies and the emerging data on immune biomarkers and SBRT, with a focus on pancreatic and liver cancer. (...) Stereotactic Body Radiation Therapy in the Management of Upper GIMalignancies The role of external beam radiation therapy (EBRT) in the management of upper gastrointestinalmalignancies is constantly evolving. As radiation therapy techniques improve and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT) allows a high dose of radiation to be delivered
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small (...) -cell lung cancer (NSCLC).Patients with advanced NSCLC treated with dacomitinib were enrolled in two cohorts. Cohort I patients were randomized 1:1 to receive oral doxycycline or placebo (4 weeks). Cohort II patients received oral VSL#3 probiotic plus topical alclometasone. Primary end points for Cohorts I and II were incidence of all grade and grade ≥2 SDAEI in the first 8 weeks of treatment and quality of life (QoL) assessed by the Skindex-16 survey. Additional primary end points for Cohort II
care Faecal immunochemical tests have the potential for correctly ruling out colorectalcancer in symptomatic patients Carlo Senore 1 , Ulrike Haug 2 , 3 Statistics from Altmetric.com Commentary on: Westwood M, Lang S, Armstrong N, et al . Faecal immunochemical tests (FIT) can help to rule out colorectalcancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med 2017 Oct 24;15:189. Context Efforts (...) aimed to increase awareness of colorectalcancer (CRC) symptoms and to reduce the proportion of cases diagnosed following an emergency presentation might result in a substantial increase in the demand for diagnostic colonoscopies, exceeding the available endoscopy capacity. The aim of this systematic review was to analyse the diagnostic performance of quantitative faecal immunochemical test (FIT) as a triage test for patients with lower abdominal symptoms. 1 Methods This is a review of diagnostic
Revised Australian national guidelines for colorectalcancer screening: family history Revised Australian national guidelines for colorectalcancer screening: family history | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Revised Australian national guidelines for colorectalcancer screening: family history Mark A Jenkins, Driss Ait Ouakrim, Alex Boussioutas, John L Hopper, Hooi C Ee, Jon D Emery, Finlay A Macrae, Albert Chetcuti, Laura Wuellner and D James B St John Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00142 Published online: 29 October 2018 Topics Abstract Introduction: Screening is an effective means for colorectalcancer prevention
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectalcancer: a randomized phase II trial-PRODIGE 20 study results. 29718089 2018 12 20 1569-8041 29 11 2018 Nov 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectalcancer: a randomized phase II trial-PRODIGE 20 study results. 2270 10.1093
, radiotherapy, resection of metastases) has increased survival in selected cases. Definition The majority of colorectalcancers are adenocarcinomas derived from epithelial cells. About 71% of new colorectalcancers arise in the colon and 29% in the rectum. Toms JR, ed. CancerStats monograph 2004. London: Cancer Research; 2004. Less common types of malignantcolorectaltumours are carcinoid tumours, GI stromal cell tumours, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal (...) adenocarcinoma with 99% of cancers occurring in people aged 40 years or over. History and exam presence of risk factors increasing age rectal bleeding change in bowel habit rectal mass positive FHx abdominal mass anaemia male sex abdominal pain weight loss and anorexia abdominal distension palpable lymph nodes increasing age APC mutation Lynch syndrome (HNPCC) MYH-associated polyposis hamartomatous polyposis syndromes inflammatory boweldisease obesity acromegaly limited physical activity lack of dietary
Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectalcancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS T Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center (...) rates and/or a largetumour size reduction (shrinkage) is recommended [II, A]. 13b. There is uncertainty surrounding the best combination to use as only a few trials have addressed this specifically: • In patients with RAS wt disease a cytotoxic doublet plus an anti-EGFR antibody seems to have the best benefit risk/ratio, although the combination of FOLFOXIRI plus or minus bevacizumab may also be considered and, to a lesser extent, a cytotoxic doublet plus bevacizumab [II, A] • In patients with RAS